Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

被引：0
|
作者：
Krieger, Laurence [1 ]
Fizazi, Karim [2 ]
Shore, Neal [3 ]
Tammela, Teuvo L. [4 ,5 ]
Ulys, Albertas [6 ]
Vjaters, Egils [7 ]
Polyakov, Sergey [8 ]
Jievaltas, Mindaugas [9 ]
Luz, Murilo [10 ]
Alekseev, Boris [11 ]
Kuss, Iris [12 ]
Le Berre, Marie-Aude [13 ]
Petrenciuc, Oana [14 ]
Snapir, Amir [15 ]
Sarapohja, Toni [15 ]
Smith, Matthew R. [16 ]
机构：
[1] Northern Canc Inst, St Leonards, NSW, Australia
[2] Univ Paris Sud, Inst Gustave Roussy, Paris, France
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Tampere Univ Hosp, Tampere, Finland
[5] Tampere Univ, Tampere, Finland
[6] NCI, Bethesda, MD 20892 USA
[7] Stradins Clin Univ Hosp, Riga, Latvia
[8] NN Alexandrov Natl Canc Ctr Belarus, Liasny, BELARUS
[9] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania
[10] Hosp Erasto Gaertner, Curitiba, Parana, Brazil
[11] Minist Hlth Russian Federat, Natl Med Res Radiol Ctr, Moscow, Russia
[12] Bayer AG, Leverkusen, Germany
[13] Bayer Healthcare SAS, Leverkusen, Germany
[14] Bayer Healthcare, Leverkusen, Germany
[15] Orion Corp Orion Pharma, Espoo, Finland
[16] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs27
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [1] Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
    Boegemann, M.
    Fizazi, K.
    Shore, N.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M. -A.
    Petrenciuc, O.
    Snapir, A.
    Sarapohja, T.
    Smith, M. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 225 - 225
  • [2] Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
    Fizazi, K.
    Shore, N. D.
    Tammela, T. L. J.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Petrenciuc, O.
    Snapir, A.
    Sarapohja, T.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S1328 - S1328
  • [3] Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Le Berre, Marie-Aude
    Petrenciuc, Oana
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
    Pang, J. S-T.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Snapir, A.
    Sarapohja, T.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Smith, M. R.
    Shore, N. D.
    Tammela, T. L. J.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1327 - S1328
  • [6] Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
    Fizazi, K.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Le Berre, M-A.
    Petrenciuc, O.
    Zurth, C.
    Kuss, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S522 - S522
  • [7] Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).
    Fuld, Alexander D.
    Young-Xu, Yinong
    Li, Sophia
    Pilon, Dominic
    Bhak, Rachel
    Duchesneau, Emilie
    Hellstern, Michael
    Kamstra, Rhiannon
    Behl, Ajay S.
    Lefebvre, Patrick
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Darolutamide for non-metastatic, castration-resistant prostate cancer
    Burki, Talha
    LANCET ONCOLOGY, 2019, 20 (03): : E139 - E139
  • [9] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2020, 15 (06) : 791 - 799
  • [10] Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2020, 15 : 791 - 799
12345